Project Description
Although inhaled products are the current standard of medial care for asthma, oral products are still underrepresented and not safe for long term use. The objective of this research is to identify agents that reduced airway hyperresponsiveness for a period of 24 hours. We have identified a new class of compound that show very promising reduction of asthma exacerbations and new agents are currently produced that hopefully exhibit a longer pharmacological effect. The methodology includes the use of A/J mice that genetically have restricted respiration and measure airway hyperresponsiveness after treatment using a whole body plethysmograph.
Tasks and Responsibilites
None specified.
Desired Qualifications
None listed.